| Patent Number |
Title Of Patent |
Date Issued |
| RE40862 |
Gossypolone for the treatment of cancer |
July 21, 2009 |
| A method for treating cancer in a human, which comprises administering to the human subject an anti-cancer effective amount of a compound selected from gossypol, gossypol acetic acid, gossypolone, metabolites thereof, or physiologically acceptable salts thereof. Also included is a method |
| RE40839 |
Taxol treatment of cancer |
July 7, 2009 |
| The present invention is a method of treatment for a patient with cancer. In particular, it is a method of treating patients having .[.lymphomas and .]. breast cancer using the microtubule agent, Taxol. The present method of administration, serves to prevent or retard the adverse side |
| RE39788 |
Gene therapy |
August 21, 2007 |
| Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy. |
| RE38424 |
Method for treating taxol side-effects with G-CSF |
February 10, 2004 |
| A method of treating a host using taxol comprising administering granulocyte colony-stimulating factor to the host being treated with taxol. The present inventive method allows for increased levels of taxol to be administered to the host in the treatment of various conditions, partic |
| RE37381 |
Vaccine against hepatitis A virus |
September 18, 2001 |
| The present invention provides an attenuated hepatitis A virus useful as a vaccine. |
| H2056 |
Model for von Hippel-Lindau disease |
December 3, 2002 |
| Disclosed herein are nucleic acid molecules that can be used to effect a loss of function of the von Hippel-Lindau (VHL) allele in somatic and/or germ cells of a mammal and methods for using these molecules to create conditional VHL gene targeted and conditional VHL knockout animals. |
| 7625736 |
Methods for preparing immunogenic conjugates |
December 1, 2009 |
| Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazino-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; |
| 7622272 |
Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology an |
November 24, 2009 |
| The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies usef |
| 7622123 |
Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
November 24, 2009 |
| Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response. Also provided are isolated polynucleotide molecules and vectors in |
| 7622113 |
Monoclonal antibodies that bind or neutralize dengue virus |
November 24, 2009 |
| The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus- |
| 7617080 |
Image enhancement by spatial linear deconvolution |
November 10, 2009 |
| Data from a target system (616) that exhibits a non-linear relationship between system properties and measurement data, is processed by applying a linear filter (F) to improve resolution and accuracy. The filter reduces inaccuracies that are introduced by an algorithm used to reconst |
| 7616984 |
Modification of the normalized difference method for real-time optical tomography |
November 10, 2009 |
| Computation-saving techniques and stability-adding techniques provide for fast, accurate reconstructions of a time series of images involving large-scale 3D problems, such as real-time image recovery in an optical tomography imaging system. A system equation for a target medium (116) |
| 7612044 |
Melanoma antigens and their use in diagnostic and therapeutic methods |
November 3, 2009 |
| The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mamma |
| 7606623 |
Methods and devices for intramuscular stimulation of upper airway and swallowing muscle groups |
October 20, 2009 |
| Devices and methods were discovered that successfully provided patient autonomous control of both hyolaryngeal elevation, anterior hyoid motion and opening of the upper esophageal sphincter for swallowing by intramuscular stimulation of two muscles. The technology allows patient self |
| 7605125 |
DNA-binding polyamide drug conjugates |
October 20, 2009 |
| A conjugate of formula: V--(Y).sub.a--Z-T: (I), T-X--B--(Y).sub.a--Z-T': (II), V--(Y).sub.a Z--(Y').sub.a V': (III), T-X--B--(Y).sub.a--Z--(Y').sub.a--X'--B'-T': (IV), V--(Y).sub.a--Z--(Y').sub.a--X--B-T: (V), V--(Y).sub.a--Z--X--B--Z'--(Y').sub.a--(V').sub.b: (VI), or (W).sub.a- |
| 7604997 |
Wipes and methods for removal of metal contamination from surfaces |
October 20, 2009 |
| Wipes, methods and kits useful for testing and/or removal of metal from surfaces (such as, dermal surfaces) are disclosed. Exemplar wipes, including the combination of a three-dimensionally textured absorbent support, a cationic surfactant, and a weak acid, are disclosed. In some exa |
| 7598225 |
Generation of immune response to prostate-specific antigen (PSA) |
October 6, 2009 |
| We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA), operably linked to a promoter capable of expression in the host, a specific humoral and cel |
| 7598077 |
Compositions and methods for enhancing differential expression |
October 6, 2009 |
| Artificial TERT promoters, which are useful for enhancing the differential expression of operably linked heterologous nucleic acid sequences, such as polypeptide cytotoxins, are disclosed herein. Methods for treating disease cells, such as cancer cells, while minimizing effects on normal |
| 7598071 |
Infectious clone of human parvovirus B19 and methods |
October 6, 2009 |
| The invention relates to infectious clones of parvovirus B19, methods of cloning infectious B19 clones, and methods of cloning viral genomes that have secondary DNA structures that are unstable in bacterial cells. A B19 infectious clone and methods of producing B19 infectious clones are |
| 7588927 |
Composition and methods relating to SENP1--a sentrin-specific protease |
September 15, 2009 |
| The invention relates to a novel protease, called SENP1, which is active against sentrin-modified proteins in vivo. The invention more specifically relates to the genomic and amino acid sequences for SENP1, compositions related to and based on these sequences, and methods of using th |
| 7585841 |
Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src |
September 8, 2009 |
| The present invention describes methods for modulating angiogenesis in tissues using Src protein, modified Src protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Src protein, or nucleic acids encodi |
| 7585667 |
Negative strand RNA virus replicon |
September 8, 2009 |
| The present invention relates to non-cytopathic negative-strand RNA virus replicons, and methods of making and using the replicons and replicon systems. |
| 7582615 |
Antisense antiviral compound and method for treating arenavirus infection |
September 1, 2009 |
| The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Arenaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Arenavirus infection in a mammal |
| 7576050 |
GLP-1 exendin-4 peptide analogs and uses thereof |
August 18, 2009 |
| The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or ex |
| 7572887 |
Gene expressed in prostate cancer, methods and use thereof |
August 11, 2009 |
| A polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Splice Variant-Novel Gene Expressed in Prostate (SV-NGEP). Polynucleotides encoding SV-NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with th |
| 7569673 |
Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors |
August 4, 2009 |
| The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity deter |
| 7566451 |
Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency |
July 28, 2009 |
| The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the |
| 7561909 |
MRI navigator methods and systems |
July 14, 2009 |
| Navigator methods are disclosed that are based on detecting a flow-sensitive signal within a subject, and using the position of the signal to track subject motion between imaging sequences. In a disclosed embodiment, the fast-moving blood volume in the left ventricle of the heart is |
| 7560118 |
Attenuated dengue virus comprising mutations in the NS3 gene |
July 14, 2009 |
| A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines. |
| 7554090 |
Apparatus and process for dose-guided radiotherapy |
June 30, 2009 |
| A method and an apparatus for dose-guided radiotherapy for a patient (P) having an identified radiotherapy target utilizes a radiation detecting array (R) of radiation-sensitive dosimeters for the real-time remote measurement of radiotherapy at the radiation detecting array (R). The |
| 7553822 |
Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene |
June 30, 2009 |
| Composition for the inhibition of the translation of a Mect1-MAML2 chimeric gene consisting essentially of: (a) a fragment of the nucleic acid encoding the chimeric gene, and (b) a nucleic acid complementary to the fragment, and a method of inhibiting the translation of a Mect1-MAML2 |
| 7547773 |
Nucleic acid molecules encoding prostate specific antigen oligo epitope peptides |
June 16, 2009 |
| The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or inter |
| 7547762 |
T24 antigen for immunodiagnosis of Taenia solium cysticercosis |
June 16, 2009 |
| The present disclosure relates to T24 nucleic acid sequences, amino acid sequences, and antibodies. Methods for detecting and diagnosing Taenia solium infection in a subject using the T24 sequences and specific binding agents are also disclosed. The T24 sequences disclosed herein can |
| 7541182 |
In vitro test to detect risk of preeclampsia |
June 2, 2009 |
| The present invention provides methods for identifying patients at risk of developing preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia. |
| 7541139 |
Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins |
June 2, 2009 |
| A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compositions are provided that include polypeptides, such as alpha defen |
| 7541043 |
Vaccine for protection against Shigella sonnei disease |
June 2, 2009 |
| Compositions and methods for protecting a susceptable host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis. |
| 7541034 |
Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
June 2, 2009 |
| Methods and compositions relating to recombinant anti-CD22 antibodies with high binding affinity, and immunoconjugates comprising the anti-CD22 antibody linked to a therapeutic agent such as a Pseudomonas exotoxin or a detectable label. The invention provides diagnostic methods, and mean |
| 7537765 |
Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer pepti |
May 26, 2009 |
| Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in |
| 7534565 |
DLC-1 gene deleted in cancers |
May 19, 2009 |
| A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thou |
| 7531352 |
Inducible plasmid vector encoding TGF-.beta. and use thereof |
May 12, 2009 |
| The present invention provides alternatives to traditional drug and surgical treatments for IBD. In particular, the present invention provides compositions and methods for the treatment of autoimmune diseases such as IBD in humans using TGF-.beta. therapy. The compositions of the pre |
| 7528274 |
Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents |
May 5, 2009 |
| Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These |
| 7527970 |
Method of identifying active chromatin domains |
May 5, 2009 |
| The invention provides a method of mapping DNA-protein interactions within a genome by fixing living cells to cross-link DNA and proteins, lysing the cells, and isolating chromatin by immunoprecipitation. DNA is purified and a SAGE protocol is performed on the purified DNA to produce |
| 7524508 |
Subgenomic replicons of the flavivirus dengue |
April 28, 2009 |
| The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection. |
| 7521479 |
Methods of treating prion disease in mammals |
April 21, 2009 |
| The invention is related to the treatment of prion-related diseases such as the transmissible spongiform encephalopathies (TSEs) in mammals by administering chaotropic agents to or inducing a hyperthermia state in the affected mammals. |
| 7521475 |
Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereo |
April 21, 2009 |
| A composition comprising a substantially purified compound of the formula: ##STR00001## in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase. |
| 7521242 |
Host cells deficient for mismatch repair and their use in methods for inducing homologous recomb |
April 21, 2009 |
| Methods are disclosed herein for inducing homologous recombination in a host cell comprising a target nucleic acid, using a single-stranded nucleic acid molecule. The single-stranded nucleic acid molecule has a sufficient number of nucleotides homologous to the target nucleic acid to |
| 7521177 |
Flavivirus detection methods employing recombinant antigens comprising a Japanese encephalitis ( |
April 21, 2009 |
| The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of |
| 7521063 |
Multiple CPG oligodeoxynucleotides and their use to induce an immune response |
April 21, 2009 |
| Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population. |
| 7521054 |
Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions o |
April 21, 2009 |
| The invention provides recombinant immunotoxins that have been modified from a parental immunotoxin to lower liver toxicity. The immunotoxins are created by specifically mutating charged residues in the framework regions of the heavy chain, the light chain, or both, of the antibody p |
| 7517531 |
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue ty |
April 14, 2009 |
| The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (.DELTA.30) in the 3'-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4. |
